(Q48093822)

8 February 2018

title

Just caring: assessing the ethical and economic costs of personalized medicine. (English)

1 reference

8 February 2018

main subject

medical ethics

0 references

personalized medicine

1 reference

Leonard M Fleck

1

1 reference

8 February 2018

publication date

1 February 2014

1 reference

8 February 2018

published in

Urologic Oncology

1 reference

8 February 2018

volume

32

1 reference

8 February 2018

issue

2

1 reference

8 February 2018

page(s)

202-206

1 reference

8 February 2018

Precision medicine for cancer patients: lessons learned and the path forward

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Just caring: health care rationing, terminal illness, and the medically least well off.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Just caring: defining a basic benefit package.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

National health spending projections through 2020: economic recovery and reform drive faster spending growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Advancing precision medicine for prostate cancer through genomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Circumventing cancer drug resistance in the era of personalized medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Gene expression profiling to dissect the complexity of cancer biology: pitfalls and promise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Tumor heterogeneity and personalized medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Combinatorial drug therapy for cancer in the post-genomic era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Development of therapeutic combinations targeting major cancer signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

Genomics-driven oncology: framework for an emerging paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.013

10.1016/J.UROLONC.2013.09.013

7 January 2021

Identifiers

DOI

1 reference

8 February 2018

PubMed ID

24445288

1 reference

8 February 2018